ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults (NCT07392723)
Alpha Linolenic Acid-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults With Mild Cognitive Impairment: Targeting Cerebrovascular and Blood-brain Barrier Health
🩺 Plain-English Summary (8th-Grade Level)
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the endogenous synthesis of docosahexaenoic acid (DHA) through ALA supplementation, the investigators aim to overcome the limitations of direct DHA supplementation, particularly in APOE4 carriers who exhibit low brain DHA levels and impaired blood-brain barrier function. This innovative approach offers a safe, cost-effective, and easily implementable therapeutic strategy for older adults at high risk for Alzheimer's dementia, especially APOE4 carriers, addressing a critical need given the limited cognitive benefits and significant adverse events of current amyloid-clearing drugs in this population.
Who can join: Review the eligibility criteria below.
Location: Rutgers - Institute for Health — New Brunswick, New Jersey
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Rutgers - Institute for Health — New Brunswick, New Jersey
📞 Contact the Study Coordinator
Phone: (848) 932-8412
Email: alastudy@njms.rutgers.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cognitive Dysfunction
- PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing — Gainesville, Florida
- Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment — Los Angeles, California
- Fareon Open Label Device Clinical Trial — New York, New York
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) — Chandler, Arizona
- Stem Cell Therapy for Early Alzheimer's Disease — Houston, Texas
Explore by condition: All Cognitive Dysfunction clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.